Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874350 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
A Phase 2 study, sponsored by Lipocine.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04874350 is a Phase 2 study that has completed, run by Lipocine. The registered enrollment target is 30 participants.
The verdict
NCT04874350, a Phase 2 study, has completed, sponsored by Lipocine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.
Interventions
- DRUG Placebo
- DRUG LPCN 1148
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04874350
The ClinicalTrials.gov registry entry for NCT04874350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lipocine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04874350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04874350 about?
NCT04874350 is a clinical study titled "A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia". This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.
What is the current status of trial NCT04874350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-11-30. Estimated completion is 2023-12-18.
What interventions are being tested in trial NCT04874350?
The interventions under investigation include: Placebo (DRUG), LPCN 1148 (DRUG).
Who is sponsoring clinical trial NCT04874350?
This trial is sponsored by Lipocine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.